ABSTRACT
Introduction: This study provides evidence of how Th1 cell metabolism is modulated by the purinergic receptor P2X7 (P2RX7), a cation cannel activated by high extracellular concentrations of adenosine triphosphate (ATP). Methods: In vivo analysis was performed in the Plasmodium chabaudi model of malaria in view of the great relevance of this infectious disease for human health, as well as the availability of data concerning Th1/Tfh differentiation. Results: We show that P2RX7 induces T-bet expression and aerobic glycolysis in splenic CD4+ T cells that respond to malaria, at a time prior to Th1/Tfh polarization. Cell-intrinsic P2RX7 signaling sustains the glycolytic pathway and causes bioenergetic mitochondrial stress in activated CD4+ T cells. We also show in vitro the phenotypic similarities of Th1-conditioned CD4+ T cells that do not express P2RX7 and those in which the glycolytic pathway is pharmacologically inhibited. In addition, in vitro ATP synthase blockade and the consequent inhibition of oxidative phosphorylation, which drives cellular metabolism for aerobic glycolysis, is sufficient to promote rapid CD4+ T cell proliferation and polarization to the Th1 profile in the absence of P2RX7. Conclusion: These data demonstrate that P2RX7-mediated metabolic reprograming for aerobic glycolysis is a key event for Th1 differentiation and suggest that ATP synthase inhibition is a downstream effect of P2RX7 signaling that potentiates the Th1 response.
Subject(s)
Glycolysis , Malaria , Receptors, Purinergic P2X7 , Th1 Cells , Animals , Mice , Mice, Inbred C57BL , Receptors, Purinergic P2X7/metabolism , Th1 Cells/cytology , Th1 Cells/metabolism , Cell Differentiation , Plasmodium chabaudi , Malaria/immunology , Adenosine Triphosphate , Adenosine Triphosphatases , Mitochondria/metabolism , T-Box Domain Proteins/metabolism , Oxidative Phosphorylation , Signal Transduction , Cells, CulturedABSTRACT
Th17 cells are recognized as indispensable in inducing protective immunity against bacteria and fungi, as they promote the integrity of mucosal epithelial barriers. It is believed that Th17 cells also play a central role in the induction of autoimmune diseases. Recent advances have evaluated Th17 effector functions during viral infections, including their critical role in the production and induction of pro-inflammatory cytokines and in the recruitment and activation of other immune cells. Thus, Th17 is involved in the induction both of pathogenicity and immunoprotective mechanisms seen in the host's immune response against viruses. However, certain Th17 cells can also modulate immune responses, since they can secrete immunosuppressive factors, such as IL-10; these cells are called non-pathogenic Th17 cells. Here, we present a brief review of Th17 cells and highlight their involvement in some virus infections. We cover these notions by highlighting the role of Th17 cells in regulating the protective and pathogenic immune response in the context of viral infections. In addition, we will be describing myocarditis and multiple sclerosis as examples of immune diseases triggered by viral infections, in which we will discuss further the roles of Th17 cells in the induction of tissue damage.
Subject(s)
Myocarditis/immunology , Th17 Cells/metabolism , Virus Diseases/immunology , Adenoviridae , Animals , Autoimmune Diseases/immunology , Chikungunya virus , Cytokines/immunology , Dengue Virus , Humans , Immune System , Immunosuppressive Agents/pharmacology , Inflammation , Interleukin-10/biosynthesis , Lymphocytes/cytology , Multiple Sclerosis/immunology , Multiple Sclerosis/metabolism , Multiple Sclerosis/virology , Myocarditis/metabolism , Myocarditis/virology , Orthomyxoviridae , SARS-CoV-2 , Simplexvirus , Th1 Cells/cytology , Th2 Cells/cytology , Virus Diseases/drug therapy , Virus Diseases/metabolism , Zika VirusABSTRACT
Mesenchymal stem cell (MSC)-based therapy is being increasingly considered a powerful opportunity for several disorders based on MSC immunoregulatory properties. Nonetheless, MSC are versatile and plastic cells that require an efficient control of their features and functions for their optimal use in clinic. Recently, we have shown that PPARß/δ is pivotal for MSC immunoregulatory and therapeutic functions. However, the role of PPARß/δ on MSC metabolic activity and the relevance of PPARß/δ metabolic control on MSC immunosuppressive properties have never been addressed. Here, we demonstrate that PPARß/δ deficiency forces MSC metabolic adaptation increasing their glycolytic activity required for their immunoregulatory functions on Th1 and Th17 cells. Additionally, we show that the inhibition of the mitochondrial production of ATP in MSC expressing PPARß/δ, promotes their metabolic switch towards aerobic glycolysis to stably enhance their immunosuppressive capacities significantly. Altogether, these data demonstrate that PPARß/δ governs the immunoregulatory potential of MSC by dictating their metabolic reprogramming and pave the way for enhancing MSC immunoregulatory properties and counteracting their versatility.
Subject(s)
Mesenchymal Stem Cells/metabolism , PPAR-beta/metabolism , Receptors, Cytoplasmic and Nuclear/metabolism , Animals , Bone Marrow Cells/cytology , CD4-Positive T-Lymphocytes/cytology , Cell Proliferation , Gene Silencing , Glycolysis , Immunosuppression Therapy , Mice , Oligomycins/chemistry , Th1 Cells/cytology , Th17 Cells/cytologyABSTRACT
Myocardial ischemia reperfusion syndrome is a complex entity where many inflammatory mediators play different roles, both to enhance myocardial infarction-derived damage and to heal injury. In such a setting, the establishment of an effective therapy to treat this condition has been elusive, perhaps because the experimental treatments have been conceived to block just one of the many pathogenic pathways of the disease, or because they thwart the tissue-repairing phase of the syndrome. Either way, we think that a discussion about the pathophysiology of the disease and the mechanisms of action of some drugs may shed some clarity on the topic.
Subject(s)
Myocardial Ischemia/pathology , Myocardial Ischemia/therapy , Reperfusion Injury/pathology , Reperfusion Injury/therapy , Animals , Humans , Immunity, Innate , Immunosuppression Therapy , Inflammation , Inflammation Mediators , Ischemia , Mice , Myocardial Infarction/therapy , Myocardial Reperfusion , Myocardial Reperfusion Injury/prevention & control , Phenotype , Th1 Cells/cytology , Th2 Cells/cytologyABSTRACT
Visceral Leishmaniasis is a chronic zoonosis and, if left untreated, can be fatal. Infected dogs have decreased cellular immunity (Th1) and develop a potent humoral response (Th2), which is not effective for elimination of the protozoan. Immune response can be modulated by microRNAs (miRNAs), however, characterization of miRNAs and their possible regulatory role in the spleen of infected dogs have not been done. We evaluated miRNA expression in splenic leukocytes (SL) from dogs naturally infected with Leishmania infantum and developing leishmaniasis (CanL; n = 8) compared to healthy dogs (n = 4). Microarray analysis showed increased expression of miR 21, miR 148a, miR 7 and miR 615, and downregulation of miR 150, miR 125a and miR 125b. Real-time PCR validated the differential expression of miR 21, miR 148a and miR 615. Further, decrease of miR 21 in SL, by means of transfection with a miR 21 inhibitor, increased the IL-12 cytokine and the T-bet/GATA-3 ratio, and decreased parasite load on SL of dogs with CanL. Taken together, these findings suggest that L. infantum infection alters splenic expression of miRNAs and that miR 21 interferes in the cellular immune response of L. infantum-infected dogs, placing this miRNA as a possible therapeutic target in CanL.
Subject(s)
Dog Diseases/diagnosis , Interleukin-12/metabolism , Leishmaniasis, Visceral/diagnosis , Leukocytes/metabolism , MicroRNAs/metabolism , Spleen/metabolism , Animals , Antagomirs/metabolism , Antibodies, Monoclonal/immunology , Dog Diseases/immunology , Dog Diseases/parasitology , Dogs , Down-Regulation , GATA3 Transcription Factor/metabolism , Immunity, Cellular , Interleukin-12/antagonists & inhibitors , Leishmania infantum/immunology , Leishmania infantum/physiology , Leishmaniasis, Visceral/immunology , Leishmaniasis, Visceral/parasitology , Leukocytes/cytology , MicroRNAs/antagonists & inhibitors , MicroRNAs/genetics , Spleen/immunology , T-Box Domain Proteins/metabolism , Th1 Cells/cytology , Th1 Cells/immunology , Th1 Cells/metabolism , Th2 Cells/cytology , Th2 Cells/immunology , Th2 Cells/metabolism , Up-RegulationABSTRACT
The aim of this study was to evaluate the influence of artesunate on Th1 differentiation and its anti-tumor effect on ovarian cancer. A Murine ovarian cancer model was established by ID8 cells transplantation. The expression of miR-142 and Sirt1 proteins in peripheral CD4+ T cells were quantified with qRT-PCR and western blot, respectively. Peripheral CD4+ T cells were induced for Th1 differentiation. The percentages of apoptosis of Th1/CD4+ T cells and ovarian cancer cells were analyzed by flow cytometry. The IFN-γ level was examined through enzyme-linked immunosorbent assay. Artesunate promoted miR-142 expression in peripheral CD4+ T cells and Th1 differentiation from CD4+ T cells. Artesunate promoted cell apoptosis of ovarian cancer cells by inducing Th1 differentiation. By up-regulating miR-142, artesunate suppressed Sirt1 level and promoted Th1 differentiation. Artesunate enhanced the pro-apoptotic effects of Th1 cells on ovarian cancer via the miR-142/Sirt1 pathway. Artesunate promoted Th1 differentiation from CD4+ T cells by down-regulating Sirt1 through miR-142, thereby enhancing cell apoptosis in ovarian cancer.
Subject(s)
Apoptosis , Artesunate/pharmacology , CD4-Positive T-Lymphocytes/drug effects , MicroRNAs/metabolism , Ovarian Neoplasms/drug therapy , Th1 Cells/drug effects , Animals , Antineoplastic Agents/pharmacology , Antineoplastic Agents/therapeutic use , Artesunate/therapeutic use , CD4-Positive T-Lymphocytes/cytology , Cell Differentiation , Down-Regulation , Female , Flow Cytometry , Mice , Mice, Inbred C57BL , Ovarian Neoplasms/immunology , Th1 Cells/cytologyABSTRACT
Neuroinflammation constitutes a fundamental process involved in Parkinson's disease (PD). Microglial cells play a central role in the outcome of neuroinflammation and consequent neurodegeneration of dopaminergic neurons in the substantia nigra. Current evidence indicates that CD4+ T-cells infiltrate the brain in PD, where they play a critical role determining the functional phenotype of microglia, thus regulating the progression of the disease. We previously demonstrated that mice bearing dopamine receptor D3 (DRD3)-deficient CD4+ T-cells are completely refractory to neuroinflammation and consequent neurodegeneration induced by the administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). In this study we aimed to determine whether DRD3-signalling is altered in peripheral blood CD4+ T-cells obtained from PD patients in comparison to healthy controls (HC). Furthermore, we evaluated the therapeutic potential of targeting DRD3 confined to CD4+ T-cells by inducing the pharmacologic antagonism or the transcriptional inhibition of DRD3-signalling in a mouse model of PD induced by the chronic administration of MPTP and probenecid (MPTPp). In vitro analyses performed in human cells showed that the frequency of peripheral blood Th1 and Th17 cells, two phenotypes favoured by DRD3-signalling, were significantly increased in PD patients. Moreover, naïve CD4+ T-cells obtained from PD patients displayed a significant higher Th1-biased differentiation in comparison with those naïve CD4+ T-cells obtained from HC. Nevertheless, DRD3 expression was selectively reduced in CD4+ T-cells obtained from PD patients. The results obtained from in vivo experiments performed in mice show that the transference of CD4+ T-cells treated ex vivo with the DRD3-selective antagonist PG01037 into MPTPp-mice resulted in a significant reduction of motor impairment, although without significant effect in neurodegeneration. Conversely, the transference of CD4+ T-cells transduced ex vivo with retroviral particles codifying for an shRNA for DRD3 into MPTPp-mice had no effects neither in motor impairment nor in neurodegeneration. Notably, the systemic antagonism of DRD3 significantly reduced both motor impairment and neurodegeneration in MPTPp mice. Our findings show a selective alteration of DRD3-signalling in CD4+ T-cells from PD patients and indicate that the selective DRD3-antagonism in this subset of lymphocytes exerts a therapeutic effect in parkinsonian animals dampening motor impairment.
Subject(s)
Benzamides/therapeutic use , CD4-Positive T-Lymphocytes/physiology , Motor Disorders/drug therapy , Parkinson Disease/immunology , Parkinsonian Disorders/drug therapy , Pyridines/therapeutic use , Receptors, Dopamine D3/physiology , Aged , Animals , Disease Models, Animal , Female , Humans , Male , Mice , Mice, Inbred C57BL , Middle Aged , Receptors, Dopamine D3/antagonists & inhibitors , Signal Transduction/physiology , Th1 Cells/cytologyABSTRACT
The aim of this study was to evaluate the influence of artesunate on Th1 differentiation and its anti-tumor effect on ovarian cancer. A Murine ovarian cancer model was established by ID8 cells transplantation. The expression of miR-142 and Sirt1 proteins in peripheral CD4+ T cells were quantified with qRT-PCR and western blot, respectively. Peripheral CD4+ T cells were induced for Th1 differentiation. The percentages of apoptosis of Th1/CD4+ T cells and ovarian cancer cells were analyzed by flow cytometry. The IFN-γ level was examined through enzyme-linked immunosorbent assay. Artesunate promoted miR-142 expression in peripheral CD4+ T cells and Th1 differentiation from CD4+ T cells. Artesunate promoted cell apoptosis of ovarian cancer cells by inducing Th1 differentiation. By up-regulating miR-142, artesunate suppressed Sirt1 level and promoted Th1 differentiation. Artesunate enhanced the pro-apoptotic effects of Th1 cells on ovarian cancer via the miR-142/Sirt1 pathway. Artesunate promoted Th1 differentiation from CD4+ T cells by down-regulating Sirt1 through miR-142, thereby enhancing cell apoptosis in ovarian cancer.
Subject(s)
Animals , Female , Rabbits , Ovarian Neoplasms/drug therapy , CD4-Positive T-Lymphocytes/drug effects , Apoptosis , Th1 Cells/drug effects , MicroRNAs/metabolism , Artesunate/pharmacology , Ovarian Neoplasms/immunology , CD4-Positive T-Lymphocytes/cytology , Down-Regulation , Cell Differentiation , Th1 Cells/cytology , Flow Cytometry , Artesunate/therapeutic use , Mice, Inbred C57BL , Antineoplastic Agents/therapeutic use , Antineoplastic Agents/pharmacologyABSTRACT
Dendritic cells (DCs) play critical functions in the initiation of immune responses. Understanding their role in reactive arthritis (ReA) will help delineate the pathogenesis of this arthropathy. In early studies, we detected IL-12/23p40 deregulation in Yersinia entercolitica (Ye)-induced ReA in TNFRp55-deficient (TNFRp55-/-) mice. In this study, we assessed the contribution of DCs in this overproduction. First, greater levels of IL-12/23p40, IFN-γand IL-17A were confirmed in supernatants of lipopolysaccharide (LPS)-stimulated TNFRp55-/-splenocytes obtained on arthritis onset (day 14 after Ye infection). Later, DCs were identified as a precise source of IL-12/23p40 since increased frequency of splenic IL-12/23p40+DCs was detected in TNFRp55-/- mice. After robust in vivo amplification of DCs by injection of Fms-like tyrosine kinase 3-Ligand (Flt3L)-transfected BL16 melanoma, DCs were purified. These cells recapitulated the higher production of IL-12/23p40 under TNFRp55deficiency. In agreement with these results, TNFRp55-/- DCs promoted Th1 and Th17 programs by co-culture with WT CD4+lymphocytes. A mechanistic study demonstrated that JNK and p38 MAPK pathways are involved in IL-12/23p40 overproduction in purified TNFRp55-/- DCs as well as in the JAWS II cell line. This deregulation was once again attributed to TNFRp55 deficiency since CAY10500, a specific inhibitor of this pathway, compromised TNF-mediated IL-12/23p40 control in LPS-stimulated WT DCs. Simultaneously, this inhibition reduced IL-10 production, suggesting its role mediating IL-12/23p40 regulation by TNFRp55 pathway. These results provide experimental data on the existence of a TNFRp55-mediated anti-inflammatory circuit in DCs. Moreover, these cells may be considered as a novel target in the treatment of ReA.
Subject(s)
Arthritis, Reactive/immunology , Dendritic Cells/immunology , Interleukin-12 Subunit p40/metabolism , Receptors, Tumor Necrosis Factor, Type I/genetics , Th1 Cells/cytology , Th17 Cells/cytology , Tumor Necrosis Factor Decoy Receptors/genetics , Yersinia Infections/complications , Yersinia enterocolitica/immunology , Animals , Arthritis, Reactive/pathology , Cell Line , Cell Polarity , Coculture Techniques , Disease Models, Animal , Humans , MAP Kinase Signaling System , Mice , Mice, Knockout , Prohibitins , Spleen/immunology , Yersinia Infections/immunologyABSTRACT
Fasciolosis is a trematode zoonosis of interest in public health and cattle production. We report here the immunostimulatory effect of a 66 mer mucin-like peptide from Fasciola hepatica (Fhmuc), which synergizes with lipopolysaccharide (LPS) to promote dendritic cell (DC) maturation, endowing these cells with Th1-polarizing capacity. Exposure of DCs to Fhmuc in presence of LPS induced enhanced secretion of pro-inflammatory cytokines and expression of co-stimulatory molecules by DCs, promoting their T cell stimulatory capacity and selectively augmenting IFN-γ secretion by allogeneic T cells. Furthermore, exposure of DCs to Fhmuc augmented LPS-induced Toll-like receptor (TLR) 4 expression on the cell surface. Finally, Fhmuc-conditioned DCs induced parasite specific-adaptive immunity with increased levels of IFN-γ secreted by splenocytes from vaccinated animals, and higher parasite-specific IgG antibodies. However, Fhmuc-treated DC conferred modest protection against F. hepatica infection highlighting the potent immuno-regulatory capacity of the parasite. In summary, this work highlights the capacity of a mucin-derived peptide from F. hepatica to enhance LPS-maturation of DCs and induce parasite-specific immune responses with potential implications in vaccination and therapeutic strategies.
Subject(s)
Cell Polarity , Dendritic Cells/metabolism , Fasciola hepatica/metabolism , Mucin-1/metabolism , Parasites/metabolism , Peptides/metabolism , Th1 Cells/cytology , Animals , Antibodies/metabolism , Antibodies, Helminth/metabolism , CD11c Antigen/metabolism , Cell Polarity/drug effects , Cytokines/metabolism , Dendritic Cells/drug effects , Fasciola hepatica/immunology , Female , Immunoglobulin G/metabolism , Inflammation Mediators/metabolism , Interferon-gamma/pharmacology , Lipopolysaccharides/pharmacology , Lymphocyte Activation/drug effects , Mice, Inbred C57BL , Models, Biological , NF-kappa B/metabolism , Parasites/immunology , Peritoneal Cavity , Signal Transduction/drug effects , Species Specificity , Spleen/pathology , Th1 Cells/drug effects , Toll-Like Receptor 4/metabolism , VaccinationABSTRACT
Multiple Sclerosis (MS) is an autoimmune disorder of the Central Nervous System that has been associated with several environmental factors, such as diet and obesity. The possible link between MS and obesity has become more interesting in recent years since the discovery of the remarkable properties of adipose tissue. Once MS is initiated, obesity can contribute to increased disease severity by negatively influencing disease progress and treatment response, but, also, obesity in early life is highly relevant as a susceptibility factor and causally related risk for late MS development. The aim of this review was to discuss recent evidence about the link between obesity, as a chronic inflammatory state, and the pathogenesis of MS as a chronic autoimmune and inflammatory disease. First, we describe the main cells involved in MS pathogenesis, both from neural tissue and from the immune system, and including a new participant, the adipocyte, focusing on their roles in MS. Second, we concentrate on the role of several adipokines that are able to participate in the mediation of the immune response in MS and on the possible cross talk between the latter. Finally, we explore recent therapy that involves the transplantation of adipocyte precursor cells for the treatment of MS.
Subject(s)
Adipokines/metabolism , Autoimmune Diseases/complications , Multiple Sclerosis/complications , Obesity/complications , Adipocytes/cytology , Adiponectin/metabolism , Adipose Tissue/pathology , Animals , Astrocytes/cytology , Autoimmune Diseases/metabolism , CD8-Positive T-Lymphocytes/cytology , Complement Factor D/metabolism , Disease Models, Animal , Encephalomyelitis, Autoimmune, Experimental/metabolism , Humans , Immune System , Inflammation , Interleukin-17/metabolism , Leptin/metabolism , Mesenchymal Stem Cells/cytology , Mice , Microglia/pathology , Multiple Sclerosis/metabolism , Nicotinamide Phosphoribosyltransferase/metabolism , Obesity/metabolism , Oligodendroglia/cytology , Prevalence , Resistin/metabolism , Risk , Th1 Cells/cytology , Th2 Cells/cytologyABSTRACT
Our understanding of how thymocytes differentiate into many subtypes has been increased progressively in its complexity. At early life, the thymus provides a suitable microenvironment with specific combination of stromal cells, growth factors, cytokines, and chemokines to induce the bone marrow lymphoid progenitor T-cell precursors into single-positive CD4(+) and CD8(+) T effectors and CD4(+)CD25(+) T-regulatory cells (Tregs). At postthymic compartments, the CD4(+) T-cells acquire distinct phenotypes which include the classical T-helper 1 (Th1), T-helper 2 (Th2), T-helper 9 (Th9), T-helper 17 (Th17), follicular helper T-cell (Tfh), and induced T-regulatory cells (iTregs), such as the regulatory type 1 cells (Tr1) and transforming growth factor-ß- (TGF-ß-) producing CD4(+) T-cells (Th3). Tregs represent only a small fraction, 5-10% in mice and 1-2% in humans, of the overall CD4(+) T-cells in lymphoid tissues but are essential for immunoregulatory circuits mediating the inhibition and expansion of all lineages of T-cells. In this paper, we first provide an overview of the major cell-intrinsic developmental programs that regulate T-cell lineage fates in thymus and periphery. Next, we introduce the SV40 immortomouse as a relevant mice model for implementation of new approaches to investigate thymus organogenesis, CD4 and CD8 development, and thymus cells tumorogenesis.
Subject(s)
CD4-Positive T-Lymphocytes/cytology , T-Lymphocytes, Regulatory/cytology , T-Lymphocytes, Regulatory/immunology , Animals , CD4-Positive T-Lymphocytes/immunology , CD8-Positive T-Lymphocytes/cytology , CD8-Positive T-Lymphocytes/immunology , Humans , Interleukin-2 Receptor alpha Subunit/metabolism , Lymphoid Tissue/cytology , Mice , Th1 Cells/cytology , Th1 Cells/immunology , Th17 Cells/cytology , Th17 Cells/immunology , Th2 Cells/cytology , Th2 Cells/immunology , Thymocytes/cytology , Thymocytes/immunologyABSTRACT
Rheumatoid arthritis (RA) is a systemic autoimmune disease in whose etiology genetic factors are known to play an important role. Among the genes associated with RA, STAT4 could be an important factor in conducting helper T cells toward the pro-inflammatory Th1 and Th17 lineages. The aim of this study is to determine the association of the STAT4 polymorphism rs7574865 with RA, disease activity, and anti-cyclic citrullinated peptide (CCP) antibody levels in a Mexican population. Genotyping was carried out using the Taqman® system from Applied Biosystems in 140 patients with RA and 150 healthy subjects. Disease activity was evaluated by a rheumatologist using the DAS28 and Spanish-HAQ-DI instruments. Anti-CCP levels were determined by ELISA. Associations of the genotypes of rs7574865 with DAS28, HAQ, and anti-CCP antibody levels with RA were determined. Findings showed that the GT and TT genotypes and the T allele from rs7574865 were all associated as risk factors for RA, independently of their anti-CCP status. An association with moderate-to-high disease activity (DAS28 ≥ 3.2) was also found. Additionally, patients with the GT or TT genotypes showed lower HAQ values than those who carried the GG genotype. No differences in anti-CCP antibody levels or DAS28 and genotypes were found. This work supports the association of the STAT4 rs7574865 polymorphism with RA and disease activity, but not with anti-CCP antibody levels in a Mexican population.
Subject(s)
Antibodies/blood , Arthritis, Rheumatoid/genetics , Peptides, Cyclic/immunology , Polymorphism, Single Nucleotide , STAT4 Transcription Factor/genetics , Adult , Aged , Alleles , Arthritis, Rheumatoid/ethnology , Case-Control Studies , Female , Gene Frequency , Genetic Predisposition to Disease , Genotype , Humans , Immunoglobulin G/blood , Male , Mexico , Middle Aged , Risk Factors , Th1 Cells/cytology , Th17 Cells/cytologyABSTRACT
Atopic dermatitis (AD), a chronic relapsing inflammatory disease of the skin, is an important public health concern affecting 10-20 % of children worldwide. The etiology and pathogenesis of AD involve the interplay of genetic and environmental factors, including abnormalities in skin integrity and a skewed immune system usually driven by a Th2 phenotype in childhood with a switch to Th1 in the chronic phase of disease. Children and adults with AD commonly have elevated IgE levels directed to multiple different antigens, including aeroallergens, food allergens, and microbial proteins. IgE targeting self-antigens from epidermal proteins have been detected in up to 91 % of patients, particularly in severe persistent AD. It has been suggested that the occurrence of autoreactivity develops in early childhood. However, it is not clear yet if autoreactive IgEs in patients with AD are pathogenic or just an epiphenomenon. The fact that these autoantibodies are associated with severity and are not present in other allergic or skin diseases favors the pathogenicity of IgE-mediated autoreactivity in AD. In this review, we evaluate the pathogenesis of AD and the emerging role of autoreactivity to various keratinocyte antigens involving both the humoral and cellular components of the immune system.
Subject(s)
Dermatitis, Atopic/immunology , Epidermis/immunology , Immunity, Cellular/immunology , Immunity, Humoral/immunology , Adolescent , Adult , Allergens/immunology , Autoantibodies/immunology , Autoantigens/immunology , Autoimmunity/immunology , Child , Dermatitis, Atopic/physiopathology , Food Hypersensitivity , Humans , Immunoglobulin E/immunology , Phenotype , Skin/immunology , Th1 Cells/cytology , Th2 Cells/cytology , Young AdultABSTRACT
We have previously found that an imbalance of Tc1/Tc2 T cell subtypes in vivo impacts the development of photodermatitis. The aim of this study was to investigate the relationship between cytokines derived from keratinocytes exposure to UV and the imbalance of Th subgroups. We used different doses of UVA and UVB to irradiate HaCaT cells. Twelve hours after irradiation, the expression of IL-10R, IL-4R, IL-12R, and IFN-γR proteins was observed using the S-P method, and the percentage of positive cells calculated. Protein levels of the respective ligands in the supernatant was measured by ELISA. Our results showed low levels of expression of the interrogated proteins in unirradiated HaCaT cells, and little or no expression could be detected in the supernatant. Little or no expression was also observed for IL-12R and IFN-γR 12 h after UVA or UVB irradiation. However, the expression of IL-10R and IL-10 was upregulated 12 h following UVB irradiation, as well as following lower dose UVA irradiation. In contrast, higher dose UVA decreased the expression of IL-10R and IL-10. The expression of IL-4R was increased following high doses of UVA and UVB irradiation, whereas no expression was observed after lower dose UV exposure. There was no change in IL-4 secretion into the supernatant. Our results demonstrate that the effects of UV exposure on keratinocyte-derived cytokines are different according to the doses of irradiation and the types of cytokines, and suggest that keratinocyte-derived cytokines after UV exposure might cause an imbalance of Th1/Th2.
Subject(s)
Cytokines/metabolism , Keratinocytes/metabolism , Keratinocytes/radiation effects , Th1 Cells/cytology , Th2 Cells/cytology , Ultraviolet Rays , Cell Line , Cell Shape/radiation effects , Enzyme-Linked Immunosorbent Assay , Humans , Immunohistochemistry , Receptors, Interferon/metabolism , Receptors, Interleukin/metabolism , Th1 Cells/radiation effects , Th2 Cells/radiation effects , Interferon gamma ReceptorABSTRACT
Interleukin-33 (IL-33) has been a focus of study because of its variety of functions shaping CD4(+) T-cell biology. In the present work, we evaluated the modulatory effect of IL-33 on suppressor cells in an in vivo transplantation model. C57BL/6 wild-type mice were grafted with syngeneic or allogeneic skin transplants and treated with exogenous IL-33 daily. After 10 days of treatment, we analysed draining lymph node cellularity and found in allogeneic animals an increment in myeloid-derived suppressor cells, which co-express MHC-II, and become enriched upon IL-33 treatment. In line with this observation, inducible nitric oxide synthase and arginase 1 expression were also increased in allogeneic animals upon IL-33 administration. In addition, IL-33 treatment up-regulated the number of Foxp3(+) regulatory T (Treg) cells in the allogeneic group, complementing the healthier integrity of the allografts and the increased allograft survival. Moreover, we demonstrate that IL-33 promotes CD4(+) T-cell expansion and conversion of CD4(+) Foxp3(-) T cells into CD4(+) Foxp3(+) Treg cells in the periphery. Lastly, the cytokine pattern of ex vivo-stimulated draining lymph nodes indicates that IL-33 dampens interferon-γ and IL-17 production, stimulating IL-10 secretion. Altogether, our work complements previous studies on the immune-modulatory activity of IL-33, showing that this cytokine affects myeloid-derived suppressor cells at the cell number and gene expression levels. More importantly, our research demonstrates for the first time that IL-33 allows for in vivo Foxp3(+) Treg cell conversion and favours an anti-inflammatory or tolerogenic state by skewing cytokine production. Therefore, our data suggest a potential use of IL-33 to prevent allograft rejection, bringing new therapeutics to the transplantation field.
Subject(s)
Graft Rejection/immunology , Graft Survival/immunology , Interleukins/pharmacology , Skin Transplantation , T-Lymphocytes, Regulatory/immunology , Animals , Arginase/biosynthesis , Cell Differentiation/immunology , Cell Proliferation , Forkhead Transcription Factors/immunology , Histocompatibility Antigens Class II/biosynthesis , Immune Tolerance/drug effects , Immune Tolerance/immunology , Interferon-gamma/biosynthesis , Interleukin-10/biosynthesis , Interleukin-10/metabolism , Interleukin-17/biosynthesis , Interleukin-33 , Lymphocyte Activation/immunology , Mice , Mice, Inbred C57BL , Myeloid Cells/immunology , Nitric Oxide Synthase Type II/biosynthesis , Skin/immunology , T-Lymphocytes, Regulatory/cytology , Th1 Cells/cytology , Th1 Cells/immunology , Th17 Cells/cytology , Th17 Cells/immunology , Transplantation, IsogeneicABSTRACT
Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis (Mtb) that is a major public health problem. The vaccine used for TB prevention is Mycobacterium bovis bacillus Calmette-Guérin (BCG), which provides variable efficacy in protecting against pulmonary TB among adults. Consequently, several groups have pursued the development of a new vaccine with a superior protective capacity to that of BCG. Here we constructed a new recombinant BCG (rBCG) vaccine expressing a fusion protein (CMX) composed of immune dominant epitopes from Ag85C, MPT51, and HspX and evaluated its immunogenicity and protection in a murine model of infection. The stability of the vaccine in vivo was maintained for up to 20 days post-vaccination. rBCG-CMX was efficiently phagocytized by peritoneal macrophages and induced nitric oxide (NO) production. Following mouse immunization, this vaccine induced a specific immune response in cells from lungs and spleen to the fusion protein and to each of the component recombinant proteins by themselves. Vaccinated mice presented higher amounts of Th1, Th17, and polyfunctional specific T cells. rBCG-CMX vaccination reduced the extension of lung lesions caused by challenge with Mtb as well as the lung bacterial load. In addition, when this vaccine was used in a prime-boost strategy together with rCMX, the lung bacterial load was lower than the result observed by BCG vaccination. This study describes the creation of a new promising vaccine for TB that we hope will be used in further studies to address its safety before proceeding to clinical trials.
Subject(s)
BCG Vaccine/immunology , Th1 Cells/immunology , Th17 Cells/immunology , Tuberculosis/prevention & control , Animals , Antigens, Bacterial/genetics , Antigens, Bacterial/metabolism , Bacterial Load/immunology , Bacterial Proteins/genetics , Bacterial Proteins/metabolism , CD4-Positive T-Lymphocytes/cytology , CD4-Positive T-Lymphocytes/immunology , Cytokines/metabolism , Epitopes/immunology , Female , Lung/metabolism , Lung/microbiology , Lung/pathology , Macrophages/cytology , Macrophages/immunology , Mice , Mice, Inbred BALB C , Mycobacterium tuberculosis/immunology , Mycobacterium tuberculosis/metabolism , Mycobacterium tuberculosis/pathogenicity , Nitric Oxide/metabolism , Peritoneum/cytology , Phagocytosis , Recombinant Fusion Proteins/biosynthesis , Recombinant Fusion Proteins/genetics , Recombinant Fusion Proteins/immunology , Spleen/immunology , Spleen/metabolism , Th1 Cells/cytology , Th17 Cells/cytology , Tuberculosis/immunologyABSTRACT
A murine model was used to study the histopathological aspects and cytokine expression levels in skeletal muscle provoked by the infection with Mexican TcI strains. BALB/c mice were inoculated with the virulent Querétaro strain and the nonvirulent Ninoa strain. Parasite numbers were counted in blood and skeletal muscle at different times post-infection, and real time-PCR expression levels of the cytokines IL-12, IL-4, IL-10, IFN- γ , and TNF- α were evaluated. In the acute phase of infection, a high parasitic load, both in blood and skeletal muscle, was detected. The histopathological analyses showed an exacerbated inflammation and granulomatous-like infiltrate with the Querétaro strain. Interestingly, extensive calcification areas were observed in the skeletal muscle surrounded by inflammatory infiltrates. TNF- α and IL-10 expression exhibited a significant increase at the peak of infection. In summary, Querétaro strain, a Mexican TcI strain, is virulent enough to induce high inflammation and calcification in skeletal muscle of the hind limbs, which could be related to high expression levels of TNF- α .
Subject(s)
Calcinosis , Inflammation/pathology , Muscle, Skeletal/pathology , Tumor Necrosis Factor-alpha/biosynthesis , Animals , Extremities , Humans , Inflammation/metabolism , Inflammation/microbiology , Interleukin-12 , Interleukin-4 , Mice , Th1 Cells/cytology , Th1 Cells/metabolism , Trypanosoma cruzi/pathogenicityABSTRACT
Experimental autoimmune encephalomyelitis (EAE) is an artificially induced demyelination of the central nervous system (CNS) that resembles multiple sclerosis in its clinical, histopathological, and immunological features. Activated Th1 and Th17 cells are thought to be the main immunological players during EAE development. This study was designed to evaluate peripheral and local contribution of IL-17 to acute and chronic EAE stages. C57BL/6 mice were immunized with MOG plus complete Freund's adjuvant followed by pertussis toxin. Mice presented an initial acute phase characterized by accentuated weight loss and high clinical score, followed by a partial recovery when the animals reached normal body weight and smaller clinical scores. Spleen cells stimulated with MOG produced significantly higher levels of IFN- γ during the acute period whereas similar IL-17 levels were produced during both disease stages. CNS-infiltrating cells stimulated with MOG produced similar amounts of IFN- γ but, IL-17 was produced only at the acute phase of EAE. The percentage of Foxp3+ Treg cells, at the spleen and CNS, was elevated during both phases. The degree of inflammation was similar at both disease stages. Partial clinical recovery observed during chronic EAE was associated with no IL-17 production and presence of Foxp3+ Treg cells in the CNS.
Subject(s)
Central Nervous System/metabolism , Encephalomyelitis, Autoimmune, Experimental/immunology , Encephalomyelitis, Autoimmune, Experimental/metabolism , Gene Expression Regulation , Interleukin-17/metabolism , Animals , Female , Forkhead Transcription Factors/metabolism , Freund's Adjuvant , Inflammation , Interferon-gamma/metabolism , Interleukin-2 Receptor alpha Subunit/metabolism , Mice , Mice, Inbred C57BL , Multiple Sclerosis/immunology , Spleen/cytology , Th1 Cells/cytology , Th17 Cells/cytologyABSTRACT
In the human immune system, T-helper cells are able to differentiate into two lymphocyte subsets: Th1 and Th2. The intracellular signaling pathways of differentiation form a dynamic regulation network by secreting distinctive types of cytokines, while differentiation is regulated by two major gene loci: T-bet and GATA-3. We developed a system dynamics model to simulate the differentiation and re-differentiation process of T-helper cells, based on gene expression levels of T-bet and GATA-3 during differentiation of these cells. We arrived at three ultimate states of the model and came to the conclusion that cell differentiation potential exists as long as the system dynamics is at an unstable equilibrium point; the T-helper cells will no longer have the potential of differentiation when the model reaches a stable equilibrium point. In addition, the time lag caused by expression of transcription factors can lead to oscillations in the secretion of cytokines during differentiation.